TO THE EDITOR:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curative therapy for patients with high-risk B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL) [1]. However, according to the EBMT database, the relapse rate of allo-HSCT recipients during their first complete remission (CR) can reach 22% [2], and post allo-HSCT relapse is associated with a disappointing remission rate and dismal outcomes [3, 4].

致编辑：异基因造血干细胞移植（allo-HSCT）仍然是高危B细胞急性淋巴细胞白血病/淋巴瘤（B-ALL/LBL）患者的治疗方法。然而，根据EBMT数据库，allo-HSCT受者在首次完全缓解（CR）期间的复发率可达到22%[2]，而allo-HSCT后复发与令人失望的缓解率和令人沮丧的结果相关[3，4]。

Therefore, it is crucial to implement strategies to mitigate the risk of relapse after allo-HSCT. Tyrosine kinase inhibitors are widely used as effective maintenance treatments for Philadelphia (Ph)-positive B-ALL [1, 5]. However, there are few reports on suitable maintenance therapies for Ph-negative B-ALL following allo-HSCT.

因此，实施减轻allo-HSCT后复发风险的策略至关重要。酪氨酸激酶抑制剂被广泛用作费城（Ph）阳性B-ALL的有效维持治疗[1，5]。然而，关于allo-HSCT后Ph阴性B-ALL的合适维持疗法的报道很少。

A single-center retrospective study suggested those with Ph-negative B-ALL may benefit from decitabine maintenance following allo-HSCT, as decitabine more than halved the 3-year relapse rate (19.5% vs. 42.2%, P = 0.068) [6]. Prophylactic donor-derived CD19 CAR-T cell infusion after allo-HSCT was reported to significantly lower the 2-year cumulative incidence of relapse in high-risk B-ALL to 5.6% [7].

一项单中心回顾性研究表明，Ph阴性B-ALL患者可能受益于异基因造血干细胞移植后地西他滨的维持治疗，因为地西他滨使3年复发率减半以上（19.5%比42.2%，P=0.068）[6]。据报道，异基因造血干细胞移植后预防性供体来源的CD19 CAR-T细胞输注可将高危B-ALL的2年累积复发率显着降低至5.6%[7]。

Recently, a phase 1 clinical trial was conducted to investigate the safety and efficacy of low-dose inotuzumab ozogamicin (INO) as a posttransplant maintenance [8]. INO demonstrated a favorable safety profile and 1-year progression-free survival (PFS) of 89%.Blinatumomab is a bispecific T-cell engager (BITE) molecule that directs CD3+ T cells to engage and lyse target CD19+ cells [9].

。INO表现出良好的安全性和89%的1年无进展生存期（PFS）。Blinatumomab是一种双特异性T细胞参与者（BITE）分子，可指导CD3+T细胞参与并裂解靶CD19+细胞（9）。

The drug was initially approved for relapsed/refractory (R/R) Ph-negative B-cell precursor (BCP)-ALL based on phase 3 of the TOWER study, and was demonstrated to result in a higher overall response rate and longer median overall surviv.

该药物最初被批准用于复发/难治性（R/R）Ph阴性B细胞前体（BCP）-ALL，基于TOWER研究的第3阶段，并被证明可导致更高的总有效率和更长的中位总生存期。

Data availability

数据可用性

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

在当前研究期间生成和/或分析的数据集可根据合理要求从通讯作者处获得。

ReferencesAcute Lymphoblastic Leukemia, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. http://www.nccn.org.Piemontese S, Boumendil A, Labopin M, Schmid C, Ciceri F, Arcese W, et al. Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT.

参考急性淋巴细胞白血病，版本4.2023，NCCN肿瘤学临床实践指南。国家综合癌症网络。http://www.nccn.org.PiemonteseS，Boumendil A，Labopin M，Schmid C，Ciceri F，Arcese W等。未经操作的单倍体相合移植后的白血病复发：代表EBMT ALWP的危险因素分析。

J Hematol Oncol. 2019;12:68.Article .

J Hematol Oncol。2019年；12： 第68条。

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Wang Z, Fan Z, Wu Z, Xuan L, Li X, Tang B, et al. PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024;204:628–37.Article .

Wang Z，Fan Z，Wu Z，Xuan L，Li X，Tang B，et al。儿童启发与成人化疗方案对异基因造血干细胞移植高危费城阴性B细胞急性淋巴细胞白血病生存率的PASS-ALL研究。Br J血液学。2024年；204:628-37。文章。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16:22.Article

Jabbour E，Short NJ，Jain N，Haddad FG，Welch MA，Ravandi F等。40年来MD Anderson急性淋巴细胞白血病研究和治疗的演变。J Hematol Oncol。2023年；16： 22、条款

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Liu H, Xuan L, Lin R, Deng L, Fan Z, Nie D, et al. A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study. Leukemia. 2021;35:2054–63.Article

Liu H，Xuan L，Lin R，Deng L，Fan Z，Nie D，et al。基于BCR/ABL监测Ph+ALL接受allo-HCT预防复发的新型先发制人TKIs策略：一项前瞻性临床队列研究。白血病。2021年；

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Fan J, Lu R, Zhu J, Guo X, Wan D, Xie X, et al. Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia. Bone Marrow Transpl. 2023;58:687–95.Article

。骨髓移植。2023年；58:687–95.文章

CAS

中科院

Google Scholar

谷歌学者

Lu W, Lyu H, Xiao X, Bai X, Zhang M, Wang J, et al. Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia. 2024. https://doi.org/10.1038/s41375-024-02251-5.Metheny LL, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, et al.

Lu W，Lyu H，Xiao X，Bai X，Zhang M，Wang J，等。预防性供体来源的CD19 CAR-T细胞输注用于预防异基因造血干细胞移植后高危B-ALL的复发。白血病。2024https://doi.org/10.1038/s41375-024-02251-5.MethenyLL，Sobecks R，Cho C，Fu P，Margevicius S，Wang J等。

A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv. 2024;8:1384–91.Article .

移植后低剂量伊妥珠单抗奥佐米星预防急性淋巴细胞白血病复发的多中心研究。血液Adv.2024；8： 1384-91年。文章。

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, et al. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024;99:586–95.Article

Jabbour E，Zugmaier G，Agrawal V，Martínez-Sánchez P，Rifón Roca JJ，Cassaday RD等。单药皮下blinatumomab治疗晚期急性淋巴细胞白血病。Am J Hematol。2024年；99:586-95.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl J Med. 2017;376:836–47.Article

Kantarjian H，Stein A，Gökbuget N，Fielding AK，Schuh AC，Ribera JM等。Blinatumomab与化疗治疗晚期急性淋巴细胞白血病的比较。N、 英国医学杂志2017；376:836-47.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–31.Article

Gökbuget N，Dombret H，Bonifacio M，Reichle A，Graux C，Faul C等。Blinatumomab治疗成人B细胞前体急性淋巴细胞白血病的微小残留病。血。2018年；131:1522–31.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Stein AS, Kantarjian H, Gökbuget N, Bargou R, Litzow MR, Rambaldi A, et al. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2019;25:1498–504.Article

Stein AS，Kantarjian H，Gökbuget N，Bargou R，Litzow MR，Rambaldi A等。Blinatumomab治疗异基因造血干细胞移植后急性淋巴细胞白血病复发。Biol骨髓移植。2019年；25:1498–504.文章

CAS

中科院

Google Scholar

谷歌学者

Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, et al. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022;139:1908–19.Article

Gaballa MR，Banerjee P，Milton DR，Jiang X，Ganesh C，Khazal S等。异基因造血细胞移植治疗B系急性淋巴细胞白血病后的Blinatumomab维持。血。2022年；139:1908-19.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Webster JA, Jones RJ, Blackford A, Shedeck A, Ambinder RF, Swinnen LJ, et al. A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance.

Webster JA，Jones RJ，Blackford A，Shedeck A，Ambinder RF，Swinnen LJ等。Blinatumomab在B细胞急性淋巴细胞白血病（ALL）和B细胞非霍奇金淋巴瘤（NHL）患者中作为异基因血液或骨髓移植（alloBMT）缓解维持的IB/II期研究。

Blood. 2023;142:3582.Article .

血。2023年；142:3582。条款。

Google Scholar

谷歌学者

Ocadlikova D, Lussana F, Fracchiolla N, Bonifacio M, Santoro L, Delia M, et al. Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study. Br J Haematol. 2023;203:637–50.Article

Ocadlikova D，Lussana F，Fracchiolla N，Bonifacio M，Santoro L，Delia M等。Blinatumomab差异调节外周血和骨髓免疫细胞库：校园ALL研究。Br J血液学。2023年；203:637–50.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAcknowledgementsThis work was supported by the National Natural Science Foundation of China (82170206) and the Shanghai Municipal Health Commission Project of Disciplines of Excellence (20234Z0002).Author informationAuthor notesThese authors contributed equally: Jiayu Huang, Bingyang Shi, Suhui Yu.Authors and AffiliationsState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, ChinaJiayu Huang & Xiaoxia HuCollaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, ChinaJiayu Huang, Ling Wang, Jieling Jiang, Jiong Hu & Xiaoxia HuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, ChinaBingyang Shi & Weijie CaoDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200136, ChinaSuhui Yu & Lijing ShenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215006, ChinaMengxing Xue & Suning ChenDepartment of Hematology, Shanghai Institute of Hematology, Blood and Marrow Transplantation Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, ChinaLing Wang, Jieling Jiang & Jiong HuGoBroad Medical Institute of Hematology (Shanghai Center), Liquan Hospital, Shanghai, 200433, ChinaJun ZhuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Scie.

下载参考文献致谢这项工作得到了国家自然科学基金（82170206）和上海市卫生委员会卓越学科项目（20234Z0002）的支持。作者信息作者注意到这些作者做出了同样的贡献：黄嘉玉，施秉阳，余苏辉。作者和所属单位上海交通大学医学院瑞金医院上海国家转化医学研究中心上海血液学研究所医学基因组学国家重点实验室，上海200025，中国黄家玉和胡晓霞上海交通大学医学院血液学协同创新中心，上海200025，中国黄家玉，王玲，蒋洁玲，胡炯和胡晓霞郑州大学第一附属医院血液学系，郑州450052，河南，上海交通大学医学院仁济医院血液学系，上海200136苏州大学第一附属医院江苏省血液病研究所国家血液病临床研究中心，血液与骨髓移植研究所，苏州大学血液学协同创新中心，苏州，215006，上海交通大学医学院瑞金医院血液与骨髓移植中心上海血液研究所血液科，上海交通大学医学院瑞金医院血液与骨髓移植中心，上海200025，王华玲，蒋洁玲，Jiong HuGoBroad血液医学研究所（上海中心），上海礼泉医院，200433，朱军华中科技大学同济医学院同济医院血液科。

PubMed Google ScholarBingyang ShiView author publicationsYou can also search for this author in

PubMed Google ScholarBingyang ShiView作者出版物您也可以在

PubMed Google ScholarSuhui YuView author publicationsYou can also search for this author in

PubMed Google ScholarSuhui YuView作者出版物您也可以在

PubMed Google ScholarMengxing XueView author publicationsYou can also search for this author in

PubMed Google ScholarmanMengxing XueView作者出版物您也可以在

PubMed Google ScholarLing WangView author publicationsYou can also search for this author in

PubMed Google学术网站WangView作者出版物您也可以在

PubMed Google ScholarJieling JiangView author publicationsYou can also search for this author in

PubMed谷歌学者Jieling JiangView作者出版物您也可以在

PubMed Google ScholarJiong HuView author publicationsYou can also search for this author in

PubMed Google ScholarJiong HuView作者出版物您也可以在

PubMed Google ScholarJun ZhuView author publicationsYou can also search for this author in

PubMed Google ScholarJun ZhuView作者出版物您也可以在

PubMed Google ScholarSuning ChenView author publicationsYou can also search for this author in

PubMed Google ScholarSuning ChenView作者出版物您也可以在

PubMed Google ScholarLijing ShenView author publicationsYou can also search for this author in

PubMed Google ScholarLijing ShenView作者出版物您也可以在

PubMed Google ScholarWeijie CaoView author publicationsYou can also search for this author in

PubMed Google ScholarWeijie CaoView作者出版物您也可以在

PubMed Google ScholarYang CaoView author publicationsYou can also search for this author in

PubMed Google ScholarYang CaoView作者出版物您也可以在

PubMed Google ScholarXiaoxia HuView author publicationsYou can also search for this author in

PubMed谷歌学者胡晓霞查看作者出版物您也可以在

PubMed Google ScholarContributionsXH, YC, WC, LS, and SC were responsible for the study design and wrote the manuscript. JH, BS and SY collected and analyzed the data and wrote the manuscript. MX, LW, JJ, JH, and JZ participated in interpreting the data. All authors read and approved the final manuscript.Corresponding authorsCorrespondence to.

PubMed Google ScholarContributionsXH，YC，WC，LS和SC负责研究设计并撰写手稿。JH，BS和SY收集并分析了数据并撰写了手稿。MX，LW，JJ，JH和JZ参与了数据的解释。所有作者都阅读并批准了最终稿件。通讯作者通讯。

Suning Chen, Lijing Shen, Weijie Cao, Yang Cao or Xiaoxia Hu.Ethics declarations

陈苏宁，沈丽晶，曹伟杰，曹杨或胡晓霞。道德宣言

Competing interests

相互竞争的利益

The authors declare no competing interests.

作者声明没有利益冲突。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Supplementary informationSupplemental MaterialsRights and permissions

Additional informationPublisher的注释Springer Nature在已发布地图和机构隶属关系中的管辖权主张方面保持中立。补充信息补充材料权利和权限

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

开放获取本文是根据知识共享署名4.0国际许可证授权的，该许可证允许以任何媒体或格式使用，共享，改编，分发和复制，只要您对原始作者和来源给予适当的信任，提供知识共享许可证的链接，并指出是否进行了更改。

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非在材料的信用额度中另有说明。如果材料未包含在文章的知识共享许可中，并且您的预期用途不受法律法规的许可或超出许可用途，则您需要直接获得版权所有者的许可。

To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/..

要查看此许可证的副本，请访问http://creativecommons.org/licenses/by/4.0/..

Reprints and permissionsAbout this articleCite this articleHuang, J., Shi, B., Yu, S. et al. Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.

。

Blood Cancer J. 14, 109 (2024). https://doi.org/10.1038/s41408-024-01092-wDownload citationReceived: 14 April 2024Revised: 26 June 2024Accepted: 27 June 2024Published: 08 July 2024DOI: https://doi.org/10.1038/s41408-024-01092-wShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

《血癌杂志》14109（2024）。https://doi.org/10.1038/s41408-024-01092-wDownload引文收到日期：2024年4月14日修订日期：2024年6月26日接受日期：2024年6月27日发布日期：2024年7月8日OI：https://doi.org/10.1038/s41408-024-01092-wShare本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供